The Pancreas SSL team (Keith Roberts and James Halle-Smith) are progressing well with COALESCE (a national CNS delivery quality improvement program aimed to support CNS at all sites and standardise pancreatic cancer care) and RADARPanc. RADARPanc is a randomised trial using the TWiC methodology led by the Dutch Pancreatic Cancer Group looking at the role of surveillance after pancreas cancer resection. We have funding for a translational study looking at the potential role of circulating tumour DNA (led by Prof Andy Beggs) and PTX3 (led by Prof Hemant Kocher) in the same setting.
We are developing trials of PERT after benign and malignant OG surgery with colleagues around the UK. My colleague Nik Chatizizacharias is running a RCT of clearance of the right side of the SMA in resectable PDAC and will have results soon (the DISSECT trial).
The one day pancreatic cancer research meeting held at the RCS was a great success in 2023 and we will continue with that this year, likely late September avoiding AUGIS. We will also run a series of webinars over the summer for trainees based upon the program Andy Smith delivered to trainees at the Leeds Pancreatic Society meeting where we break a Whipple down to its component parts and focus upon each at one webinar. There will then be a Q and A session for the trainees in person at the RCS one day pancreas cancer research event 9th October.
June 2024